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Estrogen sulfotransferase (EST) is a cytosolic
sulfotransferase that transfers a sulfuryl group
from the ubiquitous sulfate donor 3´-phospho-
adenosine 5´-phosphosulfate (PAPS) to the
3-hydroxyl on 17β-estradiol (E2). The sul-
fonation of E2 makes the compound more
soluble for renal excretion as well as for the
creation of inactive stores of sulfated E2 that
can be desulfated by steroid sulfatases
(Coughtrie et al. 1998). Both the estrogen
receptor (ER) and EST have afﬁnities for E2
in the nanomolar range, thus suggesting that
EST may play an important role in the regula-
tion of estrogenic effects by controlling the
levels of E2 (Adams 1991; Falany and Falany
1996). The ability of EST to mediate local
estrogen concentration has been demonstrated
in mice by gene disruption studies (Qian et al.
2001; Tong and Song 2002).
Recently, it has been shown that some
hydroxylated polychlorinated biphenyls
(OH-PCBs) can inhibit human EST (hEST)
(Kester et al. 2000). PCBs are persistent man-
made environmental pollutants found in ter-
restrial and aquatic systems. These compounds
and their metabolites accumulate in mammals
and have been suggested to be endocrine dis-
ruptors based on links with disturbance of sex-
ual development and reproductive function
(Brouwer et al. 1999; Cheek et al. 1998). The
pathway by which these compounds exert
their toxic effect is not well understood.
However, the OH-PCBs (4-OH-PCBs espe-
cially) share structural similarities, such as a
phenolic ring, with E2 and may exert their
endocrine effects by mimicking E2 binding to
various proteins. Many endocrine disruptors
exert their toxic effects through interactions
with the ER. It has previously been demon-
strated that PCB metabolites can bind the ER
(Connor et al. 1997; Korach et al. 1988).
Some PCB metabolites such as OH-PCBs and
PCB-catechols are capable of stimulating in
vitro translocation of ER into the nucleus and
binding to the ER response elements (Connor
et al. 1997; Garner et al. 1999; Korach et al.
1997). However, the concentrations required
to elicit this response is two to three orders of
magnitude greater than E2, thus questioning
the signiﬁcance of this pathway for endocrine
disruption in the presence of physiologically
relevant amounts of PCBs accumulated from
environmental exposure.
Interestingly, PCBs inhibit hEST with
IC50 (concentration that inhibits 50%) values
as low as 0.1 nM (Kester et al. 2000). This
level is roughly 40-fold lower than the Km for
the substrate E2. Thus, the study by Kester et
al. suggests that a possible mechanism for
endocrine disruption by PCBs and their
hydroxylated metabolites may be an indirect
effect whereby inhibition of hEST by OH-
PCBs enhances estrogenic activity by increas-
ing the levels of E2 in target tissues.
Based on Lineweaver-Burk plots, Kester
et al. (2000) suggest that the inhibition by
OH-PCBs appears to be noncompetitive.
Based on kinetic data, it has previously been
reported that hEST may contain an allosteric
site (Zhang et al. 1998). Therefore, Kester et
al. proposed that the mode of inhibition may
be due to OH-PCB binding to this allosteric
site (Kester et al. 2000).
To address the question of how OH-PCBs
interact with hEST, we have determined the
crystal structure of hEST in complex with the
sulfuryl donor product PAP and with the most
effective inhibitor reported by Kester et al.,
4,4´-OH-3,5,3´,5´-tetraCB (Kester et al.
2000). Previously we determined the crystal
structures of hEST in the presence of the sul-
furyl donor PAPS and in complex with PAP
(donor product) and E2 (Pedersen et al. 2002).
In the E2 complex structure, the E2 molecule is
bound in a hydrophobic pocket with the accep-
tor 3-hydroxyl within hydrogen bonding dis-
tance to histidine 107, the proposed catalytic
base (Kakuta et al. 1997; Pedersen et al. 2002).
This positions the 3-hydroxyl for an in-line
nucleophilic attack on the sulfur atom of PAPS
to form the sulfated product. In this study we
found 4,4´-OH-3,5,3´,5´-tetraCB in the active
site binding in the same position as the E2 sub-
strate. Such binding suggests competitive inhi-
bition. Although we do not attempt to validate
the role or mode of endocrine disruption by
PCBs and their metabolites, this study clearly
shows that certain OH-PCBs are capable of
mimicking E2binding to hEST. 
Materials and Methods
Protein for the wild-type hEST was expressed
and purified as previously described for the
V269E mutant (Pedersen et al. 2002). We
obtained crystals of hEST using the sitting drop
vapor diffusion technique. Protein concen-
trated at 15 mg/mL in 0.5 mM monosodium
phosphate, 100 mM sodium chloride, and
4 mM PAP at pH 7.5 was mixed in equal vol-
ume with 0.1 M 2-[N-morpholino]ethane sul-
fonic acid, pH 6.0, and 18% polyethylene
glycol 8000, then placed at 20°C. Typical crys-
tals appeared after 10 days and grew to 0.5 mm
× 0.5 mm × 0.02 mm after 1 month. For data
collection, crystals were transferred to 0.1 M
2-[N-morpholino]ethane sulfonic acid, pH
6.0, 22% polyethylene glycol 8000, and 4
mM PAP, followed by an overnight soak in
either saturated 1,3,5 (10)-estratrien-2,4-
dibromo-3,17β-diol (E2Br2) or 4,4´-OH-
3,5,3´,5´-tetraCB. Crystals were then
transferred in four steps of increasing ethylene
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tion of 15% ethylene glycol in the soaking
solution was obtained. The crystals were ﬂash-
frozen in a nitrogen stream at –180°C. Data
were collected on a RaxisIV image plate detec-
tor with a RU3H rotating anode generator
(Rigaku/MSC Inc., Woodlands, TX) (Table
1). All data were processed using Denzo and
Scalepack programs (Otwinowski and Minor
1997). Coordinates with Protein Data Bank
(PDB) identification code of 1HY3 of the
V269E mutant of hEST were used as the
starting coordinates for reﬁnement. The pro-
gram “O” was used for model building (Jones
et al. 1991) and CNS for reﬁnement (Brünger
et al. 1998). We checked the quality of the
models using PROCHECK (Table 1) (Bailey
1994). Coordinates for E2Br2 and PCB were
obtained from the Cambridge Structural Data
Base (Cody et al. 1971; McKinney and Singh
1988). The coordinates have been submitted
to the PDB and given the PDB identiﬁcation
code 1G3M.
Results
In the crystal structure of hEST in the pres-
ence of PAP and E2, the E2 molecule is
located in a hydrophobic substrate binding
pocket (Pedersen et al. 2002). The acceptor
3-hydroxyl group is located 2.6 Å from NZ of
K105 and 2.8 Å from NE2 of H107 [single
letter abbreviation code used for amino acid
residues (i.e., histidine 107 = H107;); atom
names used are based on PDB format].
Residues lining the substrate binding pocket
near the active site include H107, K105, Y168,
Y239, F141, F23, M247, Y81, V145, and
C83. In this study, 4,4´-OH-3,5,3´,5´-tetraCB
binds in the active site of hEST in a position
similar to that of the E2 molecule (Figure 1).
Like the E2 molecule, binding of 4,4´-OH-
3,5,3´,5´-tetraCB appears to induce no obvi-
ous conformational change in residues lining
the substrate binding pocket. Superposition of
the protein molecules from the hEST + PAP +
4,4´-OH-3,5,3´,5´-tetraCB to that of hEST +
PAP + E2 places the 4-hydroxyl group of the
OH-PCB in a location similar to the 3-
hydroxyl of E2, but offset approximately 1 Å
from its position (Figure 2). The 4-hydroxyl
group is 3.1 Å from NZ of K105 and 2.8 Å
from NE2 of H107 (Figures 1A, 3B). Thus the
4-hydroxyl of the inhibitor is able to form the
same interactions with these residues as the
3-hydroxyl of the acceptor substrate E2
(Figures 3B, 3C) (Pedersen et al. 2002). The
phenol ring containing the 4-hydroxyl is also
shifted 1 Å with respect to the A ring of the
E2, and the plane of the ring is raised out of
the plane of the A ring of E2 by about 12°
(Figure 2A). The remaining phenol ring of
4,4´-OH-3,5,3´,5´-tetraCB is rotated ~30° out
of the plane of the ﬁrst ring (Figure 2C). The
4´-hydroxyl is located 3.1 Å from A146 and
2.9 Å from a water molecule that is also 2.8 Å
from OD2 of D22 (Figures 1B, 3A). These
interactions with the 4´-hydroxyl might help
to increase the binding affinity to hEST for
this particular OH-PCB.
The torsion angle of 30° differs from
that of the solid-state crystal structure, which
is a coplanar structure (torsion angle 0°)
(McKinney and Singh 1988). Interestingly,
energy calculations for the possible torsion
Table 1. Crystallographic data statistics.
PAP + 
Data set 4,4´-OH-3,5,3´,5´-tetraCB PAP + E2Br2
Unit cell dimensions a = 62.69, b = 96.89, c = 61.72 a = 61.16, b = 96.97, c = 62.52
α = 90°, β = 92.58°, δ = 90° α = 90°, β = 92.70°, δ = 90°
Space group P21 P21
No. of observations 151,066 139,656
Unique reﬂections 75,359 60,218
Rsym (%) (last shell)a 5.8 (26.2) 5.2 (31.2)
I/σI (last shell) 8.4 (1.9) 9.7 (1.7)
Mosaicity 0.57 0.61
Completeness (%) (last shell) 92.6 (82.9) 88.8 (73.9)
Reﬁnement statistics
Resolution (Å) 50–1.7 50–1.8
Rcryst (%)b 19.3 19.0
Rfree
c 21.9 22.0
No. of waters 603 469
RMSD from ideal values
Bond length (Å) 0.006 0.006
Bond angle (°) 1.2 1.2
Dihedral angle (°) 21.1 21.0
Improper angle (°) 0.76 0.77
Mean B value (Å2) 21.4 27.2
Ramachandran statistics
Residues in
Most-favored regions (%) 93.0 91.5
Additionally allowed regions 6.8 8.3
Generously allowed regions 0.0 0.0
Disallowed regions 0.2 0.2
Abbreviations: cryst, crystal; RMSD, root–mean–square deviation; sym, symmetry. 
aRsym = Σ (| Ii – <I>|)/ Σ(Ii), where Ii is the intensity of the ith observation and <I> is the mean intensity of the reﬂection.
bRcryst = Σ|| Fo| – | Fc ||/ Σ| Fo| calculated from working data set. cRfree is calculated from 5% of data randomly chosen not
to be included in reﬁnement.
Figure 1. (A) Cartoon diagram of the crystal structure of human EST (yellow) in the presence of donor product
PAP (green) and the PCB inhibitor 4,4´-OH-3,5,3´,5´-tetraCB (orange). The chlorides have been labeled 3, 3´, 5,
and 5´. Also pictured is the proposed catalytic base H107 (blue). (B) Active site of hEST with 4,4´-OH-3,5,3´,5´-
tetraCB bound. Side chains within 4.4 Å are displayed. The OH-PCB molecule is shown in orange, the PAP
molecule in green, backbone trace in khaki, side chain atoms in blue, and water molecules as red spheres.
The fo-fc annealed omit map for PAP and 4,4´-OH-3,5,3´,5´-tetraCB is shown contoured at 3σ (blue). Possible
hydrogen bonds are represented with black dashed lines, and chlorides have been labeled as 3,3´5, and 5´.
Figure 1 was created using MOLSCRIPT (Kraulis 1991) and RASTER3D (Merritt and Bacon 1997).
A B
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similar to the one used in our study, suggest
the energy minimum is at 42° with a maxi-
mum at 0° of 3.7 kcal/mol (McKinney et al.
1983). At 30°, the energy barrier is calculated
to be around 0.4 kcal/mol, suggesting the tor-
sion angle in the crystal structure for
4,4´-OH-3,5,3´,5´-tetraCB is in a lower
energy orientation than in the solid-state crys-
tal structure. The 30° torsion angle found in
the protein crystal structure complex pre-
sented here is in good agreement with another
energy calculation that predicts a minima in
the torsion angle at 32° for an unsubstituted
biphenyl (Almlöf 1974).
To examine what role the chlorines at
positions 3 and 5 may have on the offset of
the phenyl group nearest the active site,
E2Br2 was soaked into the crystal. E2Br2
appears to bind in a location similar to that of
E2, but is shifted in the direction of the 4,4´-
OH-3,5,3´,5´-tetraCB, suggesting that the
halides in the ortho position to the 4-hydroxyl
may play a role in this shift (Figure 2). In
addition, this result suggests that other halides
such as Br can substitute for Cl at the posi-
tions adjacent to the hydroxyl on the phenol
ring for binding to hEST.
Discussion
It has been suggested that 4,4´-OH-3,5,3´,5´-
tetraCB is an extremely effective noncompeti-
tive inhibitor to the hEST enzyme, with IC50
values in the low nanomolar range (Kester et
al. 2000). Those studies indicate that the
OH-PCBs may bind primarily to a proposed
allosteric site. The current crystal structure,
however, places the PCB molecule in the E2
position in the active site. Binding at this posi-
tion implies competitive inhibition is to be
expected. Although there has been no crystal-
lographic evidence of an additional binding
site in any EST structure, both the PAP + E2
and PAP + 4,4´-OH-3,5,3´,5´-tetraCB crystal
structures were obtained by soaking the sub-
strate or inhibitor into the preformed crystal.
Therefore, if a major conformational change is
required for binding to the additional site, or if
this site were positioned at a crystallographic
interface, it is unlikely that we would observe
binding. Consequently, the existence of this
site cannot be ruled out. However, supporting
the crystallographic data, previous inhibition
studies of the sulfonation of 3,3´-diiodothyro-
nine by cytosolic sulfotransferases using 4-OH-
2´,3,3´,4´,5-pentaCB suggest the inhibition
mechanism is competitive (Schuur et al. 1998). 
In general, the position of the 4,4´-OH-
3,5,3´,5´-tetraCB molecule in the hEST crys-
tal structure is consistent with the IC50 results
of the various PCB molecules tested by Kester
et al. (2000). Using OH-PCBs with an iden-
tical 4-hydroxy-3,5-dichloro–substituted phe-
nolic ring. Kester et al. noted that especially
potent inhibition was observed for 3´,4´ substi-
tution and 3´,5´ substitution with Cl atoms.
The current orientation of 4,4´-OH-3,5,3´,5´-
tetraCB bound to hEST could accommodate
both of these types of substitution without
major steric clashes. As shown by our crystal
structure, substitutions at the 3-, 3´-, 5-, and
5´-positions are easily tolerated (Figures 2, 3A).
Addition of chlorine atoms at the 3- ,3´-, 5-,
and 5´-positions increases the surface area of
the PCB molecule, which could allow for
greater Van der Waal interactions between
4,4´-OH-3,5,3´,5´-tetraCB and hEST, thus
increasing the binding affinity. In addition,
positioning of a hydroxyl group at the 4-posi-
tion would allow for strong hydrogen bond-
ing interactions with the NZ atom of K105
and the NE2 atom of H107. The conforma-
tion and position of 4,4´-OH-3,5,3´,5´-
tetraCB in the active site could allow for OH
or Cl substitution at the 3,3´-, 4´-, 5-, 5´-,
and possibly the 4-position. Chlorine atoms
are capable of forming hydrogen bonds, but
they are typically longer than N…H–O
hydrogen bonds, suggesting a slight rearrange-
ment in side chains 107 and 105, and possible
slight positioning change of the molecule
would be required for these compounds with
chlorines in the 4-position to bind in the same
orientation.
Other substitutions are also possible. 
Based on the current position, substitutions
at the 2- or 2´-position can occur without
large Van der Waal conﬂicts with the protein
(Figure 3A). In addition, a slight change in
the torsion angle to 45° from planar would
lower the predicted rotational potential
energy from 12 kcal/mol to 4 kcal/mol,
which is the same rotational potential for the
coplanar arrangement of an unsubstituted
biphenyl (McKinney et al. 1983). However,
substitution at the 6- or 6´-position would
create large Van der Waal conﬂicts with Y20
(Figure 3A).
Based on the position of the 4,4´-OH-
3,3´,3´,5´ tetraCB to hEST, models of six of
the seven PCBs with the lowest IC50 values
(IC50 < 1nM) can be easily accommodated.
Molecules 4-OH-2,3,5,3´,4´-pentaCB (IC50
0.15–0.25nM), 4-OH-3,5´,3´,4´-tetraCB
(IC50 0.21–0.61nM), 4-OH-3,5,3´,5´-tetraCB
(IC50 0.47–1.0), 4-OH-3,5,2´,3´,4´-pentaCB
(IC50 0.28–0.30), and 4-OH-3,5,3´,4´,5´-
pentaCB should all be able to ﬁt into the active
site with the same orientation as the 4,4´-OH-
3,3´,3´,5´-tetraCB molecule used in this study.
In addition, the seventh molecule 4-OH-
2,3,5,2´,3´,4´-hexaCB (IC50 0.27–0.75) might
be able to bind without much change. A rota-
tion of 180° of the second phenyl ring in
Figure 3 would be required so the 2 and 2´
occupants would not create a bad steric con-
tact. This conformation might cause a slight
Van der Waal interaction between the 2´ Cl
and Y20 that could possibly be alleviated
by minor rearrangement of the molecule or
side chains.
Using the same principles, all the remain-
ing molecules with IC50 values < 50nM could
also be accommodated, with one exception:
molecule 4-OH-2,3,5,6,2´,4´,5´-heptaCB
(IC50 6.8–30). In general, the best inhibitors
from the study of Kester et al. (2000) (IC50s <
5nM) do not have substitution at the 2- and
the 6-position. The 6-position Cl in the cur-
rent orientation would have a major Van der
Waal contact with Y20, and because there are
Figure 2. (A) Orientation of the ligands from the superposition of the complexes of hEST with 4,4´-OH-3,5,3´,5´-tetraCB (carbons orange, chlorides magenta), E2
(carbons green), E2Br2 (carbons blue, bromines yellow) bound in the active site; this ﬁgure shows an approximate 12° shift of the PCB and E2Br2 phenolic rings
from that of the E2 substrate. (B) Rotation of (A) by approximately 90° along a horizontal axis; the phenolic ring of 4,4´-OH-3,5,3´,5´-tetraCB containing the 4 OH is
slightly offset from the phenolic ring of the E2 substrate. (C) Rotation of (A) by 90° along a vertical axis; the 3 OH of E2 is located out of the plane of the page. (C)
Clearly shows the approximate 30° twist in the second phenolic ring of 4,4´-OH-3,5,3´,5´-tetraCB from that of the ﬁrst ring. The visible chlorides have been labeled
in (A), (B), and (C). These ﬁgures were created using MOLSCRIPT (Kraulis 1991) and RASTER3D (Merritt and Bacon 1997).
A B C
3’ 3’
5’ 5
3
5’
5 3
3’
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(2,6,2´) on the phenyl rings, this molecule
would most likely have to have a torsion angle
near 90° between the two phenyl rings. Thus,
the binding of this particular molecule cannot
be explained by the current position of the
PCB molecule.
In conclusion, these studies support the
notion that certain OH-PCBs are capable of
binding to hEST and inhibiting its function as
shown by Kester et al. (2000). The OH-PCB
molecule 4,4´-OH-3,5,3´,5´-tetraCB binds at
the E2 binding position in the active site, sug-
gesting competitive inhibition. Thus, for the
ﬁrst time, the crystal structure of hEST in the
presence of PAP and 4,4´-OH-3,5,3´,5´-
tetraCB provides atomic detail of a hydroxy-
lated PCB compound mimicking hormone
binding to protein molecules.
Although it is not clear what effect envi-
ronmental exposure to PCBs has on the proper
function of hEST in vivo, the kinetic data by
Kester et al. (2000), combined with the crystal-
lography presented in this study, suggest that
future studies are warranted.
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